1 / 4

Stelara: As An Monoclonal Antibody

Stelara is a monoclonal antibody, authorized for the treatment of adults and children aged 6 years and older with moderate or severe psoriasis. It is used in adults aged 18 years and older with active psoriatic arthritis. The stelara 45 mg can be used alone or together with the medication methotrexate. It is also used in dults 18 years and older with moderately to severely active Crohnu2019s diseasedisease and active ulcerative colitis. This medication should be administered subcutaneously.

jhon28
Download Presentation

Stelara: As An Monoclonal Antibody

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Stelara ustekinumab PLAQUE PSORIASIS PSORIATIC ARTHRITIS CROHN’S DISEASE

  2. Stelara Common Side Effects • cold symptoms (stuffy nose, sneezing, sore throat), • headache, • tired feeling, • diarrhea, or. • skin rash or itching.

  3. Stelara is an immunosuppressive medication containing Ustekinumab as an active pharmaceutical ingredient, that is a genetically engineered monoclonal antibody launched to be administered by subcutaneous (SC) injection in the treatment of psoriasis and psoriatic arthritis. Stelara is also aimed to treat moderately to severely active Crohn’s disease (CD) who have unsuccessful or were not tolerant to therapy with immunomodulators or corticosteroids, but never unsuccessful a TNF blocker (Tumor Necrosis Factor) or unsuccessful or were not tolerant to therapy with one or more tumor necrosis factor blockers. Stelara, supplied as 45 mg and 90 mg, is a subcutaneous injection intended for use under the appropriate guidance as well as supervision of a health specialist with patients who wiII be precisely monitored and have regular follow-up. The respective patients may self-inject with Stelara 45 mg after health specialist approval and apt training. Stelara acts in order to disrupt some interleukins involved in the immune response. USTEKINUMAB INFORMATION FOR PATIENTS AND CAREGIVERS

More Related